



MAYNE PHARMA EXPECTS NO MATERIAL IMPACT TO EARNINGS PROFILE FROM US PHARMACEUTICAL TARIFF PROCLAMATION

Key Points:

- New Section 232 tariff proclamation announced by US President on 2 April 2026
- No material impact on Mayne Pharma's FY27 earnings profile expected based on current proclamation
- No material impact expected for Mayne Pharma's Women's Health portfolio
- Entire US dermatology generics portfolio (representing 16% of 1H FY26 revenue mix) expected to be exempt from tariffs under the proclamation
- Mayne Pharma will update the market as necessary as it undertakes further detailed analysis of its portfolio, with particular reference to API origin, formulation and finishing of certain products and as tariff calculations are adjusted

7 April 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces a preliminary assessment of the likely impact of the 2 April 2026 (US time) proclamation signed by the US President imposing a 100% Section 232 tariff on certain imported patented pharmaceuticals and associated active pharmaceutical ingredients (APIs) and key starting materials, into the US, effective 31 July 2026 for larger companies and 29 September 2026 for smaller companies. Mayne Pharma is not on the list of larger companies and therefore subject to the 30 September 2026 date. Generic pharmaceuticals and their associated ingredients are not subject to tariffs pursuant to Section 232 at this time.

Mayne Pharma **does not anticipate a material impact** to the Company's earnings profile as a result of the new Section 232 tariff, specifically owing to:

- (1) Minimal tariff applicable to the Company's Women's Health portfolio (only one API potentially impacted for two menopause products)
- (2) Zero tariff applicable to generic dermatology medicines (16% of 1H FY26 revenue mix)
- (3) Other branded dermatology products are largely manufactured in the US

For the Company's Women's Health segment, Mayne Pharma believes the tariffs would not apply to the contraceptives in the branded portfolio and would not have a material effect on the menopause products as only one API is sourced internationally, and that API is sourced from a territory under an existing trade deal with the US and subject to a lower tariff.

Generic dermatology pharmaceuticals sold by Mayne Pharma in the United States currently comprise 16% of Mayne Pharma's 1H FY26 product revenues appear to be specifically exempted from the new Section 232 tariffs for at least one year. Several of the Company's branded dermatology products may be subject to the new Section 232 tariffs; however, at this time, Mayne Pharma does not believe the application of these tariffs will result in a material impact to the



ASX Announcement

Dermatology segment contribution. Although several APIs are sourced internationally (including from territories under existing trade deals with the US) the cost of these APIs comprise a relatively minor component of the overall cost of goods. Branded products formulated and finished predominately in the US are not subject to a Section 232 tariff.

As it relates to the Company's Salisbury, South Australia manufacturing facility, minimal impact, if any, is currently expected as most products produced for export to the US are generic products, and therefore the overall impact to the International business contribution is not considered material.

As currently provided in the proclamation, the imposition of any such tariffs would commence from 29 September 2026 (i.e. Q2 FY27).

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Chair.

Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.